Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

19.28 

0.18 0.9%

as of Feb 21 '20

52 Week Range:

15.40 22.12


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 2.18
2.18
2.49
2.58
2.62
2.70
3.71
4.24
8.09
7.54
4.99
growth rate 0.0% 14.2% 3.6% 1.6% 3.1% 37.4% 14.3% 90.8% -6.8% -33.8%
Earnings BIT 39.42
58.35
74.48
57.80
81.28
395.00
419.00
393.00
401.00
336.00
429.00
growth rate 48.0% 27.6% -22.4% 40.6% 386.0% 6.1% -6.2% 2.0% -16.2% 27.7%
Avg.PE 17.30
20.58
24.94
23.58
24.33
18.48
15.72
15.05
30.23
0.00
14.76
growth rate 19.0% 21.2% -5.5% 3.2% -24.0% -14.9% -4.3% 100.9% -100.0%
ROA 6.14
7.81
9.31
5.99
6.07
11.59
13.30
10.40
4.45
-21.75
8.19
growth rate 27.2% 19.2% -35.7% 1.3% 90.9% 14.8% -21.8% -57.2% -100.0% 100.0%
ROE 11.18
12.15
13.92
10.54
12.47
22.92
25.11
19.89
8.30
-43.12
17.63
growth rate 8.7% 14.6% -24.3% 18.3% 83.8% 9.6% -20.8% -58.3% -100.0% 100.0%
ROIC 8.99
9.84
11.68
8.33
8.63
15.80
18.05
14.77
7.13
-28.96
13.83
growth rate 9.5% 18.7% -28.7% 3.6% 83.1% 14.2% -18.2% -51.7% -100.0% 100.0%
Cur. Ratio 1.82
2.23
1.89
1.69
1.67
1.53
1.20
2.30
1.58
1.97
1.87
growth rate 22.5% -15.3% -10.6% -1.2% -8.4% -21.6% 91.7% -31.3% 24.7% -5.1%
Quick Ratio 1.08
1.37
1.08
1.04
1.00
0.94
0.79
1.66
0.99
1.20
1.09
growth rate 26.9% -21.2% -3.7% -3.9% -6.0% -16.0% 110.1% -40.4% 21.2% -9.2%
Leverage 1.60
1.51
1.48
2.02
2.08
1.90
1.88
1.94
1.82
2.24
2.08
growth rate -5.6% -2.0% 36.5% 3.0% -8.7% -1.1% 3.2% -6.2% 23.1% -7.1%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 173.96
203.25
230.00
299.00
304.00
400.00
406.00
450.00
715.00
716.00
745.00
growth rate 16.8% 13.2% 30.0% 1.7% 31.6% 1.5% 10.8% 58.9% 0.1% 4.1%
Acct.Payable 75.00
98.00
110.00
120.00
129.00
139.00
172.00
218.00
263.00
growth rate 30.7% 12.2% 9.1% 7.5% 7.8% 23.7% 26.7% 20.6%
Cur.Assets 415.21
456.60
494.00
660.00
782.00
897.00
1,013.00
1,360.00
1,448.00
1,574.00
1,668.00
growth rate 10.0% 8.2% 33.6% 18.5% 14.7% 12.9% 34.3% 6.5% 8.7% 6.0%
Total Assets 586.57
629.57
1,116.00
1,576.00
1,730.00
1,929.00
2,251.00
2,597.00
4,363.00
3,388.00
3,497.00
growth rate 7.3% 77.3% 41.2% 9.8% 11.5% 16.7% 15.4% 68.0% -22.4% 3.2%
Cash 38.54
41.86
63.00
95.00
177.00
168.00
280.00
553.00
155.00
227.00
276.00
growth rate 8.6% 50.5% 50.8% 86.3% -5.1% 66.7% 97.5% -72.0% 46.5% 21.6%
Inventory 154.76
160.51
182.00
239.00
272.00
276.00
273.00
251.00
459.00
488.00
528.00
growth rate 3.7% 13.4% 31.3% 13.8% 1.5% -1.1% -8.1% 82.9% 6.3% 8.2%
Cur.Liabilities 228.43
204.44
269.00
389.00
467.00
586.00
841.00
592.00
918.00
797.00
893.00
growth rate -10.5% 31.6% 44.6% 20.1% 25.5% 43.5% -29.6% 55.1% -13.2% 12.1%
Liabilities 216.97
213.49
366.00
777.00
882.00
895.00
1,035.00
1,245.00
1,952.00
1,860.00
1,800.00
growth rate -1.6% 71.4% 112.3% 13.5% 1.5% 15.6% 20.3% 56.8% -4.7% -3.2%
LT Debt 70.34
75.60
78.00
345.00
376.00
264.00
145.00
590.00
721.00
670.00
539.00
growth rate 7.5% 3.2% 342.3% 9.0% -29.8% -45.1% 306.9% 22.2% -7.1% -19.6%
Equity 369.60
420.64
461.88
491.62
522.03
1,017.00
1,197.00
1,337.00
2,396.00
1,514.00
1,685.00
growth rate 13.8% 9.8% 6.4% 6.2% 94.8% 17.7% 11.7% 79.2% -36.8% 11.3%
Common Shares 193.00
194.00
197.00
198.00
198.00
198.00
200.00
201.00
234.00
241.00
242.00
growth rate 0.5% 1.6% 0.5% 0.0% 0.0% 1.0% 0.5% 16.4% 3.0% 0.4%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 38.42
23.39
49.00
69.00
51.00
59.00
91.00
82.00
122.00
107.00
107.00
growth rate -39.1% 109.5% 40.8% -26.1% 15.7% 54.2% -9.9% 48.8% -12.3% 0.0%
Cash Dividends 8.62
9.91
14.22
15.51
16.62
33.00
39.00
52.00
77.00
79.00
84.00
growth rate 15.0% 43.5% 9.1% 7.1% 98.5% 18.2% 33.3% 48.1% 2.6% 6.3%
Cash From OA 35.14
64.95
153.00
126.00
184.00
337.00
425.00
366.00
293.00
443.00
430.00
growth rate 84.8% 135.6% -17.7% 46.0% 83.2% 26.1% -13.9% -20.0% 51.2% -2.9%
FCF per Share -0.02
0.21
0.28
0.07
0.28
0.63
0.97
0.79
0.60
0.78
0.85
growth rate 100.0% 33.3% -75.0% 300.0% 125.0% 54.0% -18.6% -24.1% 30.0% 9.0%
Sale Purchase of Stock 2.00
1.00
1.00
growth rate -50.0% 0.0%
FCF -8.00
65.00
86.00
25.00
92.00
262.00
307.00
229.00
103.00
292.00
291.00
growth rate 100.0% 32.3% -70.9% 268.0% 184.8% 17.2% -25.4% -55.0% 183.5% -0.3%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 352.43
392.08
731.00
918.00
1,109.00
1,365.00
1,489.00
1,440.00
1,950.00
1,936.00
2,070.00
growth rate 11.3% 86.4% 25.6% 20.8% 23.1% 9.1% -3.3% 35.4% -0.7% 6.9%
Op.Income 80.70
107.30
100.00
83.00
107.00
395.00
419.00
393.00
401.00
336.00
429.00
growth rate 33.0% -6.8% -17.0% 28.9% 269.2% 6.1% -6.2% 2.0% -16.2% 27.7%
IBT 38.84
58.36
74.49
57.80
81.26
298.00
362.00
318.00
210.00
-738.00
293.00
growth rate 50.3% 27.6% -22.4% 40.6% 266.7% 21.5% -12.2% -34.0% -100.0% 100.0%
Net Income 34.65
47.83
100.00
83.00
107.00
212.00
278.00
252.00
155.00
-843.00
282.00
growth rate 38.0% 109.1% -17.0% 28.9% 98.1% 31.1% -9.4% -38.5% -100.0% 100.0%
EPS 0.29
0.40
0.50
0.41
0.51
1.07
1.39
1.25
0.66
-3.51
1.17
growth rate 37.9% 25.0% -18.0% 24.4% 109.8% 29.9% -10.1% -47.2% -100.0% 100.0%
Gross Profit 155.67
187.39
344.00
383.00
485.00
717.00
819.00
818.00
950.00
915.00
1,004.00
growth rate 20.4% 83.6% 11.3% 26.6% 47.8% 14.2% -0.1% 16.1% -3.7% 9.7%
R&D 31.00
55.00
36.00
126.00
115.00
118.00
growth rate 77.4% -34.6% 250.0% -8.7% 2.6%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 99.50
115.00
115.00
117.50
117.50
growth rate 15.6% 0.0% 2.2% 0.0%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 662.00
745.00
745.00
687.00
687.00
growth rate 12.5% 0.0% -7.8% 0.0%
Acct.Payable 219.00
263.00
263.00
248.00
248.00
growth rate 20.1% 0.0% -5.7% 0.0%
Cur.Assets 1,545.00
1,668.00
1,668.00
1,699.00
1,699.00
growth rate 8.0% 0.0% 1.9% 0.0%
Total Assets 3,346.00
3,497.00
3,497.00
3,606.00
3,606.00
growth rate 4.5% 0.0% 3.1% 0.0%
Cash 220.00
276.00
276.00
322.00
322.00
growth rate 25.5% 0.0% 16.7% 0.0%
Inventory 534.00
528.00
528.00
579.00
579.00
growth rate -1.1% 0.0% 9.7% 0.0%
Cur.Liabilities 814.00
893.00
893.00
1,324.00
1,324.00
growth rate 9.7% 0.0% 48.3% 0.0%
Liabilities 1,804.00
1,800.00
1,800.00
1,762.00
1,762.00
growth rate -0.2% 0.0% -2.1% 0.0%
LT Debt 608.00
539.00
539.00
40.00
40.00
growth rate -11.4% 0.0% -92.6% 0.0%
Equity 1,529.00
1,685.00
1,685.00
1,832.00
1,832.00
growth rate 10.2% 0.0% 8.7% 0.0%
Common Shares 40.00
40.00
40.00
40.00
40.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 26.50
27.00
27.00
24.00
24.00
growth rate 1.9% 0.0% -11.1% 0.0%
Cash Dividends 27.50
14.50
14.50
31.50
31.50
growth rate -47.3% 0.0% 117.2% 0.0%
Cash From OA 92.50
122.50
122.50
93.50
93.50
growth rate 32.4% 0.0% -23.7% 0.0%
FCF 66.00
95.50
95.50
69.50
69.50
growth rate 44.7% 0.0% -27.2% 0.0%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 494.50
540.50
540.50
523.50
523.50
growth rate 9.3% 0.0% -3.2% 0.0%
Op.Income 99.50
115.00
115.00
117.50
117.50
growth rate 15.6% 0.0% 2.2% 0.0%
IBT 70.50
76.00
76.00
113.00
113.00
growth rate 7.8% 0.0% 48.7% 0.0%
Net Income 53.00
88.00
88.00
92.50
92.50
growth rate 66.0% 0.0% 5.1% 0.0%
Gross Profit 239.00
263.00
263.00
262.00
262.00
growth rate 10.0% 0.0% -0.4% 0.0%
R&D 23.50
35.50
35.50
29.00
29.00
growth rate 51.1% 0.0% -18.3% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (66.69)

YOY Growth Grade:

D (45.90)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 12.95 12.96 14.38
EPS / Growth -6.6% 1.49 12.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 11.4%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 8.3% 8.3%
Future PE 2.00 14.61 14.61
Future EPS 1.64 3.29 3.29
Value Price
MOS %
0.81
-95.8%
11.87
-38.4%
11.87
-38.4%
MOS Price 0.41 5.94 5.94
IRT 12.13 8.66 8.66

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.